Summary We performed an experimental study on slow releasing anticancer drug implantation treatment as a new therapy for hepatocellular carcinoma. Hydroxyapatite (HAP) was chosen for the carrier material and doxorubicin hydrochloride (DOX) for anticancer agent. DOX-HAP was produced by adsorbing DOX to porous HAP particles of 1375 ± 125 gm diameter using the freeze drying method. In vitro experiments showed slow release of the drug resulting in the steady release of DOX from HAP for I month duration. In healthy white rabbits with DOX-HAP implantation in the liver, serum DOX was not detectable, and DOX release rate was stable at the implanted region after 7, 14, and 21 days. When DOX-HAP (DOX; 100mg kg-') was administered to mice with sarcoma 180, an improved survival rate was observed without acute toxicity.
The introduction of interventional injection of Podophyllin (Semple, 1948) and intraarterial injection of nitrogen mustard (Bierman et al., 1950; Klopp et al., 1950) , has facilitated the development of targeting therapies for malignant solid tumours, such as selective intraarterial or intratissue injection of anticancer drugs, which aim at the prolongation of the effect of anticancer drugs. Anticancer drugs, however, have a very low therapeutic index because of their strong cytotoxicity and the large dosage required to produce the desired effect. To overcome these problems, targeting chemotherapy with drug-carrier complexes was invented, using a microcapsule (Kato et al., 1980) , fat (Takahashi et al., 1973) , carbon (Hagiwara et al., 1987) , dextran (Hashida et al., 1981) , and lipiodol (Konno et al., 1983 (Konno et al., , 1984 .
We selected hydroxyapatite (HAP) as a drug-carrier based on its confirmed safety as an osteofilling. We produced a slow-releasing anticancer drug complex, DOX-HAP by physically adsorbing doxorubicin (DOX) to HAP by a freeze drying method. The implantation of this complex was done with the guidance of ultra-sound. The properties and anticancer effect of this implantation therapy were investigated in the transplantable tumours, VX2 carcinoma and sarcoma 180(S-180).
Materials and methods
Preparation of DOX-HAP HAP is an inorganic substance analogous to bone, with a structural formula of Ca,0(PO4)6(OH)2 and a base material with a Ca/P atomic ratio of 1.67. The substrate was prepared by mixing Ca(OH)2 and H3PO4 employing a precipitation method (Uchida et al., 1985 (10, 15, 20, 40, 60, 80 and 100mgkg-', n=20 ) and intraperitoneally (i.p.) (5, 10, 15, 20, 30 and 40mg kg', n = 20) and non-treated mice (n = 20) were prepared as control groups. The tumour volumes were then measured until their size reached to 1,500 mm3. The anticancer effect was evaluated by LDM/7 and by tumour growth time (t.g.time). LD50/7 was defined as the DOX dose which gave a 50% survival rate within 7 days, and t.g.time as the days which were required for a tumour to reach 1,500 mm3 from the first treatment day. These two parameters were calculated by logit analysis (Urano & Kahn, 1987) . The survival rate of the HAP group (DOX; 100 mg kg-') was evaluated by KaplanMeier method (Kaplan & Meier, 1958) .
The tumours were removed from the HAP group (DOX; 100 mg kg-') after 1, 3, 5, and 7 days of implantation. They were then treated with formalin, paraffin embedding, and hematoxylin-eosin stained, after which histologic analysis was performed.
VX2 tumour VX2 tumour in the femoral muscle of the white rabbit was removed aseptically after 4 weeks of implantation. 
Results

Assay of release of DOX in vitro study
The in vitro release pattern of DOX from DOX-HAP showed that 33% of DOX was eluted by the 3rd day, but a stable, slow 1% per day release was observed between the 5th and 28th days and 56% of the total DOX was eluted by the 28th day (Figure 2 ).
Rabbit study
In the rabbit study, the DOX concentration in the blood was always below a measurable level in the HAP group. However, it was 6.91 fig g-' at 15 s after injection of only DOX.
After 45 min, it dropped back below a measurable level. In the implanted tissue the HAP group had a peak of 41.0 fg g-' of DOX concentration on the 3rd day, a decrease to a plateau level of 10.3 jig g-' on the 14th day and 10.8 ig g-' on the 21st day. The only DOX group, however, showed a gradual and continuous decrease in DOX concentration from 18.6igg-' at 6h to below a measurable level on the 7th day. The DOX concentrations in the heart, lung, kidney, and left lobe of the liver were under the measurable limit in the HAP group after 1 day, but remained measurable in the only DOX group until the 3rd day (Table I) . (Figure 4 ).
The times taken to reach a tumour volume of 1,500mm3 were 21.9 (20.2-23.8) days for the 100mgkg-' group, 18.1 (16.5-20.1) days for the 60mgkg-', and 14.6 (9.8-17.2) days for the 20mgkg-' compared to 7.93 (7.80-8.11) days for the control group. Administration of HAP alone accelerated tumour growth probably due to its physical stimulation. Figure 5 represents the tumour growth time (Y) as a function of DOX dose (X). In the HAP group, a linear-regression curve of y = 0.14 x + 9.29 (r = 0.98) was obtained.
In the 50% survival of the ddY mice, there was a remarkable difference between the HAP group (70.0 days) and the non-treated group (41 days). In the i.p. group, 50% survival was 49 days. In addition, 30% of the mice in the HAP group were still alive even after 120 days and these mice were cured. On histological examination of S-180 1 day after implantation, hemorrhagic necrosis and phagocyte infiltration were observed under integument and around HAP. Three days later, the area of necrosis spread continuously with phagocytes around HAP. Five days later, vacuolation of tumour cells, hyperplasia of fibrous tissues, and oncolysis expansion around vessels at a distant area from the HAP were observed. Seven days later, oncolysis expanded and phagocyte infiltration around the remaining tumour cells was noted.
Anticancer effect on VX2 tumour VX2 tumour volume ratios [Va(7)/Vb] of non-treated group, the i.t. group, and the HAP group were 18.6 ± 6.5, therapies include intraarterial chemotherapy (Doppman et al., 1968; Goldstein et al., 1976; Klopp et al., 1950) , embolisation therapy (Nakamura et al., 1983; Yamada et al., 1983) , and percutaneous ethanol injection into hepatocellular carcinoma (Seki et al., 1989 (Seki et al., , 1991 Sugiura et al., 1983) . However, there is a demand for a treatment which has a less liver -and general toxicity or systemic side effect, in addition to the local anticancer effect. Targeting therapies, using a microcapsule, fat, and lipiodol methods have recently improved (Audisio et al., 1990; Gregoriadis, 1977; Kato, 1983; Kato et al., 1980 Kato et al., , 1984 Konno et al., 1983 Konno et al., , 1984 Widder et al., 1979 ). These methods were made possible by primary targeting through the nutrient artery of the tumour and complete secondary targeting by adding the embolisation effect. For patients with arterial shunt or tumour embolism, however, these methods are not effective and retention of drugs in the tumours is unreliable in many cases. In this study, since DOX-HAP implantation therapy had a greater survival rate than i.t. group and i.p. group, it is clear that DOX-HAP implantation therapy is an effective method for the tumour treatment.
We have developed a new method of slow release of an anticancer agent using a carrier material implanted into a liver tumour under an ultrasonic guide. After considering safety, convenience (Uchida et al., 1985 (Uchida et al., , 1989 , and possibility of repetition, we chose HAP for the carrier material. Saito et al. (1987) , has previously reported the anticancer effect of HAP with DOX injected in the tumour of hepatocellular carcinoma patient. However, from her experiments, it was not clear whether the effect was due to the direct treatment or to the slow release of DOX. To address this issue we produced 1,375 ± 125 ,Lm diameter particles by sintering HAP powder which could pass through a biopsy needle. The advantages of our method include the reduction of the material moved into the vessels and easy confirmation of its location by ultrasound. We have produced a slow release anticancer agent, DOX-HAP, by physical adsorption of DOX to the surface and inner space of HAP by using freeze drying method. Recently, the manifestation of the DOX effect has been considered to be strongly correlated with the contact duration (Ozawa et al., 1988 (Ozawa et al., , 1989 . For this reason we chose DOX which is comparatively effective on the hepatoma. Some discrepancies exist between the results of our in vitro and in vivo experiments, which we believe can be explained by considering the time required for DOX to elute into the blood stream around the implantation area. Once the DOX began to elute, it displayed a stable slow release pattern compared with other slow releasing agents. Our study on rabbits showed that the DOX concentrations in serum and organs other than the implanted area were always below a measurable level and the high dose experiment on mice with a tumour did not demonstrate any acute toxicity.
The anticancer effect of DOX-HAP on S-180 depended on the dosage, however, tumour growth inhibition was offset by high mortality due to acute toxicity in high doses in i.t. groups and i.p. groups. Pathological examination revealed an increase of tumour-necrosis around the implantation area and the appearance of necrotic tissue around vessels until 7 days after the procedure. This led us to believe that DOX-HAP produced an anticancer effect not only around the implantation area, but eluted free DOX in the blood stream resulting in the expansion of the necrotic area.
We believe that DOX-HAP implantation therapy is an effective treatment with an efficient drug delivery system. We also discover that careful choice of implantation area and joint use of other therapies, such as embolisation therapy and percutaneous ethanol injection, are required to increase the anti-tumour effect.
